The human papillomavirus (HPV) vaccines Gardasil and Gardasil 9 have established dominance in the cervical cancer vaccine market. As of Q3, their market share has reached 99.9%.

Following the expanded vaccination age limit and increase in domestic supply price, the quarterly sales of these vaccines increased to 35.3 billion won. Gardasil 9’s sales may increase even further if President Yoon Suk Yeol include it into the National Immunization Program (NIP), as pledged.

Q3 Gardasil and Gardasil 9 sales 35.3 bil…Market share of 99.9%

According to clinical research firm IQVIA, the sales of MSD's Gardasil and Gardasil 9 in Q3 were 35.3 billion won, a 5% increase from 33.6 b